Check-Cap Ltd. is a clinical stage medical diagnostics company, which engages in the development of ingestible imaging capsule systems for colorectal cancer screening. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.
根据最新的财务报表(Form-10K),Check Cap Ltd 的总资产为 $0,净损失为 $0
MBAI 的关键财务比率是什么?
Check Cap Ltd 的流动比率是 0,净利 margin 为 0,每股销售为 $0。
Check Cap Ltd 的收入按细分市场或地理位置如何划分?
Check Cap Ltd 最大收入来源是 Center-of-the-Plate,在最近的收益报告中收入为 1,455,274,000。就地区而言, United States, Middle East, and Canada 是 Check Cap Ltd 的主要市场,收入为 3,794,212,000。